Our findings align with those reported in several animal models of CKD, particularly regarding tubulointerstitial fibrosis, where MMP-9 increases and TIMP-1 decreases their expressions with quercetin treatments, both with macroparticles and nanoparticles [51,52]. This evidence concerns the gene MMP9 and chronic kidney disease.